fda approval semaglutide A big win for Wegovy: Weight loss drug first in history to gain for reducing heart risks FDA Clears Semaglutide For Cardiac

Researchers have commented that the peptide appears to cause increases in mean plasma GH concentrations by 2- to 10-fold [...] and in mean plasma IGF-I concentrations by 1.5- to 3-fold... [2] CJC-1295 has been primarily researched for its potential in mitigating actions frequently associated with cell aging

While monthly GLP-1 formulations may become commercially available soon in higher-income regions, other geographies especially those with high expected biosimilar penetration may continue relying on weekly-dosed drugs for the foreseeable future

Animal studies demonstrate enhanced angiogenesis and collagen formation in tendon and ligament injuries

Effects of semaglutide on glycemic control and safety in patients with type 2 diabetes

Like other GLP1 drugs, CagriSema is a once-weekly subcutaneous injection